Ferritin to Transferrin Ratio: a new prognostic factor for renal cell carcinoma.

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

Urologia Internationalis Pub Date : 2025-01-22 DOI:10.1159/000543589

Huadong Xie, Yuanbi Huang, Huajie He, Rongchao Chen, Yongpeng Li, Haoyuan Lu, Xianlin Yi

{"title":"Ferritin to Transferrin Ratio: a new prognostic factor for renal cell carcinoma.","authors":"Huadong Xie, Yuanbi Huang, Huajie He, Rongchao Chen, Yongpeng Li, Haoyuan Lu, Xianlin Yi","doi":"10.1159/000543589","DOIUrl":null,"url":null,"abstract":"Objectives: To assess the prognostic value of the preoperative serum ferritin-to-transferrin ratio (FTR) in renal cell carcinoma (RCC). Methods：We retrospectively reviewed data from 226 patients who underwent surgery for non-metastatic RCC at our institution between January 1, 2012, and June 30, 2021. Time-dependent receiver operating characteristic (timeROC) analysis identified the optimal FTR cut-off, dividing patients into high and low FTR groups. Propensity score matching (PSM) adjusted for baseline differences. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression, with a nomogram validating the results.Results: The timeROC analysis showed a 5-year area under the curve (AUC) of 0.786 for FTR, with 68.4% sensitivity and 86.7% specificity at a cut-off of 177.1. High FTR and clinical stage were independent risk factors for OS and RFS. The hazard ratios (HR) for OS and RFS in the high and low FTR groups were 2.598(1.087-6.213), P=0.032 and 2.591(1.105-6.074), P=0.029, respectively. Kaplan-Meier curves showed significant differences post-PSM (log rank P<0.05). The nomogram validation indicated high predictive accuracy with a C-index of 0.867 (95% CI: 0.836-0.899) for OS and 0.808 (95% CI: 0.764-0.852) for RFS. Conclusion：Our findings suggest that FTR may serve as an independent prognostic risk factor in patients with locally and locally advanced renal cell carcinoma.","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-16"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543589","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To assess the prognostic value of the preoperative serum ferritin-to-transferrin ratio (FTR) in renal cell carcinoma (RCC). Methods：We retrospectively reviewed data from 226 patients who underwent surgery for non-metastatic RCC at our institution between January 1, 2012, and June 30, 2021. Time-dependent receiver operating characteristic (timeROC) analysis identified the optimal FTR cut-off, dividing patients into high and low FTR groups. Propensity score matching (PSM) adjusted for baseline differences. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression, with a nomogram validating the results.

Results: The timeROC analysis showed a 5-year area under the curve (AUC) of 0.786 for FTR, with 68.4% sensitivity and 86.7% specificity at a cut-off of 177.1. High FTR and clinical stage were independent risk factors for OS and RFS. The hazard ratios (HR) for OS and RFS in the high and low FTR groups were 2.598(1.087-6.213), P=0.032 and 2.591(1.105-6.074), P=0.029, respectively. Kaplan-Meier curves showed significant differences post-PSM (log rank P<0.05). The nomogram validation indicated high predictive accuracy with a C-index of 0.867 (95% CI: 0.836-0.899) for OS and 0.808 (95% CI: 0.764-0.852) for RFS. Conclusion：Our findings suggest that FTR may serve as an independent prognostic risk factor in patients with locally and locally advanced renal cell carcinoma.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologia Internationalis 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.